Immunomodulators for Asthma by Dimov, Vesselin V & Casale, Thomas B
228 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org
INTRODUCTION
New information regarding the molecular mechanisms of al-
lergic disorders has led to a variety of novel therapeutic ap-
proaches. This article will briefly review the pathogenesis of 
asthma and allergic diseases; discuss the rationale behind us-
ing immunomodulators in these diseases; and examine the 
therapeutic effects of immunomodulators on allergic diseases. 
This review will focus on immunomodulators that are in hu-
man clinical trials and not molecules in pre-clinical develop-
ment.
One might question why new treatments are needed when 
with the advent of new and better inhaled corticosteroids with 
and without long-acting B-agonists many individuals with asth-
ma are well controlled. However, as with all treatments, inhaled 
corticosteroids are not effective for all individuals. Indeed, about 
30%-35% of individuals, both adult and pediatric patients with 
asthma, have a poor or no response to inhaled corticosteroids. 
Furthermore, inhaled corticosteroids have not been shown to 
prevent the progression of disease or completely reverse airway 
remodeling.
1,2 
Thus, there is a need for novel therapies that affect critical im-
munopathologic mechanisms and that would induce immune 
tolerance; that is, change the immune system such that the ther-
apy might actually be able to be discontinued with continued 
maintenance of disease control long term.
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ASTHMA PATHOGENESIS
The pathogenesis of asthma involves a number of different 
cells, mediators, and cytokines (Figure). It is also apparent that 
particular pathways or molecules may be more important in in-
dividual patients. Thus, finding a universal treatment that would 
be clinically beneficial for all patients is a challenge.
One of the first steps important in the pathogenesis of allergic 
respiratory diseases is antigen capture and presentation. This is 
followed by engagement of the T-cell receptor and CD3 com-
plex by MHC class II molecules on B cells. Subsequently, there 
is a chain of molecular events including engagement of CD154 
(CD40L) on Th2 cells and CD40 on B cells, along with engage-
ment of CD28 and CD80/86 on Th2 and B cells respectively. 
These events ultimately lead to the release of important cytok-
ines such as IL-4 and IL-13 critical for immunoglobulin E (IgE) 
production. Once IgE is produced, it binds to mast cells and ba-
sophils where cross-linking of high affinity IgE receptors bound 
by IgE and antigen leads to mediator and cytokine release. Im-
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portant in this process is the release of more IL-4 and IL-13 from 
a number of different inflammatory cells including mast cells, 
as well as IL-9. These cytokines are important to propagate the 
production of IgE and allergic inflammation in general. IL-5 
and GM CSF are also produced and these are key molecules for 
growth and differentiation of eosinophils. Eosinophils are key 
immune effector cells that can leave the blood vessel through 
the interactions of adhesion molecules and chemoattractants 
and migrate to the site of inflammation. This process involves a 
number of different molecules in addition to those mentioned 
above, many of which have been targets of therapeutic inter-
ventions.
Strategies to inhibit inflammatory pathways are many and in-
clude targeting the cell of origin of inflammatory cytokines and 
mediators, targeting the released mediator or cytokine, or in-
hibiting the effects of the released cytokine or mediator by block-
ing the mediated effects on the target cell. All of these approach-
es have been undertaken with various molecules. For example, 
soluble receptors and monoclonal antibodies against key cy-
tokines such as IL-4 have undergone clinical trials. Inhibitors of 
target cell receptors for these molecules have also been studied. 
This review will focus on many different approaches by exam-
ining the clinical effectiveness of novel immunomodulators in-
volved in key pathogenic mechanisms.
STRATEGIES AIMED AT T-CELLS
Due to the pro-inflammatory role of activated T-cells in asth-
matic airways and the observed correlation of increased CD25 
expression with asthma severity, attempts have been made to 
block this arm of allergic disease pathogenesis. Initial attempts 
included monoclonal antibodies against Th2 cells such as ke-
liximab. Although this treatment showed some modest im-
provement in patients with severe asthma, because of the po-
tential side effects, it has not been extensively studied.
Cyclosporine and tacrolimus have similar mechanisms inhib-
iting T cells and have been used for the treatment of severe asth-
ma. Cyclosporine in early studies was shown to improve pul-
monary functions in severe asthmatics, but because of side ef-
fects it has not been used extensively. An inhaled form of tac-
rolimus was used in patients with asthma, but was unsuccess-
ful in meeting primary endpoints.
Daclizumab is a humanized monoclonal IgG1 antibody that 
is currently approved for the prevention of renal allograft rejec-
tion. It is specific for CD25 expressed by activated T-cells and 
inhibits IL-2 stimulated proliferation by blocking the IL-2 re-
Figure. Asthma pathogenesis adapted from Casale et al.
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ceptor alpha chain. It does not deplete circulating CD25+ cells 
however. In a study by Busse et al. in 2008,
3 moderate to severe 
asthma patients were placed on intravenous daclizumab. They 
showed improved pulmonary functions, reduced asthma symp-
toms and rescue medication use, increased time to severe ex-
acerbations, and reduced peripheral blood eosinophil and se-
rum eosinophil cationic protein levels. These investigators found 
greater activity in a refractory asthma subgroup. In that group, 
daclizumab resulted in approximately 10% improvement in 
FEV1 values, whereas patients on placebo had approximately 
10% decrease in FEV1. There was also a two-thirds reduction in 
the number of asthma exacerbations in patients treated with 
daclizumab versus placebo. Thus far, a subcutaneous formula-
tion has not been tried for asthma so it unclear whether or not 
this will be a potentially viable treatment for patients with asth-
ma. 
Another approach to target T lymphocytes and other key cells 
important in the pathogenesis of allergic respiratory diseases is 
to use ligands of toll-like receptors (TLR). Thirteen different toll-
like receptors have been described in humans. Mycobacteria 
activate toll-like receptors 1 and 2, and the use of attenuated 
strains has been tried in humans, with minimal to no effect. 
There is much more information, however, on the use of TLR-4 
and TLR-9 agonists. 
The ligand for TLR-4 receptors is endotoxin/lipid A. A specific 
form of this, monophosphoryl lipid A (MPL) has been used as 
monotherapy as well as in combination with allergen immuno-
therapy for the treatment of allergic diseases. Ultra short course 
vaccines containing MPL have been used since the 1970’s for 
seasonal allergic rhinitis from grass, tree or ragweed. The cur-
rent preparation includes a glutaraldehyde-modified antigen 
absorbed onto L-tyrosine depot to enhance tolerability plus 
MPL to improve efficacy via activation of toll-4 receptors. Sev-
eral trials have shown that four pre-seasonal injections of this 
preparation can reduce symptoms and medication use, elevate 
antigen-specific IgG and blunt seasonal elevations of IgE. Re-
cent United States trials have shown positive results for both 
grass and ragweed allergies. In a study presented at the Europe-
an Academy of Allergy and Clinical Immunology meeting in 
2008, Zielen et al.,
4 showed that an ultra short course specific 
immunotherapy with Polinex Quattro
TM in pediatric and ado-
lescent patients resulted in improvement in patients treated 
three consecutive years pre-pollen season. In addition, the 
amount of improvement in patients was greater in years 2 and 
3. These data suggest that this approach of four pre-seasonal in-
jections might be appropriate to use in controlling patients who 
have significant seasonal allergic rhinitis.
Immunostimulatory DNA molecules, CpG, have been used as 
well to treat allergic respiratory diseases. TLR-9 agonists have 
been used as monotherapy and conjugated to antigen in hu-
man clinical trials. Initial human experiments showed that im-
munostimulatory CpG molecules linked to the predominant 
short ragweed allergen, Amb a1, stimulates an antigen-specific 
Th2 to Th1 shift and improves the safety margin of allergen im-
munotherapy. In a study by Creticos et al.,
5 twenty-five subjects 
with seasonal allergic rhinitis due to ragweed were given six pre-
seasonal injections of Tolamba
TM, the combination of Amb a1 
plus CpG conjugated to each other, in increasing doses from 
0.06 to 12 mcg. The investigators found improvements in symp-
toms in the year the patients were treated as well as the subse-
quent year with no further treatment. There was an approxi-
mate 50% reduction in symptoms in both years with decreased 
rescue medication and improvement in quality of life. Howev-
er, large scale clinical trials have been disappointing. Although 
there were technical difficulties with the larger studies that may 
account for the disappointing results, the utility of this approach 
has been questioned and further clinical trials are not currently 
planned. 
However, another approach using a TLR-9 agonist has been 
shown to be effective. CYT003-QbG10, is a novel immunother-
apy agent that consists of a virus-like particle, Qb and a short 
stretch of DNA from mycrobacteria that activates toll-like re-
ceptor 9 present in dendritic and other cells. In a recent publi-
cation by Senti et al.,
6 CYT003-QbG10 plus house dust mite al-
lergen was given for ten weeks to human subjects with asthma 
and allergic rhinitis. These investigators found improvements 
in symptom scores and quality of life for up to 48 weeks. Inhibi-
tion of skin test responses to house dust mite was also sustained 
for up to 48 weeks. This implies that long after discontinuing 
treatment there is sustained clinical improvement. Interesting-
ly, in an eighty patient seasonal allergic rhinitis study, total rhi-
noconjunctivitis symptom scores were shown to be improved 
with QbG10 molecule without allergen.
7 The treatment ap-
peared safe and well tolerated, and efficacious in lowering rhi-
noconjunctivitis symptoms. Since this latter study did not use 
an allergen, it is concluded that CYT 003 acts through an aller-
gen-independent mechanism and not through an adjuvant ef-
fect. A phase IIIb study with 300 patients suffering from peren-
nial allergies has recently been started.
Another approach targeting T-cells and the early phases of al-
lergic inflammation has been to use peroxisome proliferator-
activated receptor (PPAR) agonists. This approach has been 
shown to be effective in murine models.
8 PPAR-gamma ago-
nists inhibit gene expression by binding to AP1 and other co-
activators inhibiting the production of important inflammatory 
cytokines. PPAR-gamma agonists have a number of potential 
mechanisms which could be important.
8 These include inhibi-
tion of cytokine production from a number of inflammatory 
cells in addition to T-lymphocytes and decreased chemotaxis 
of inflammatory cells. Human clinical trials are under way and 
it will be interesting to see whether these agents, already used 
for Type II diabetes mellitus (glitazones), might also be effective 
for asthma.Immunomodulators for Asthma AAIR 
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Table. Monoclonal antibodies (mAb) and fusion proteins in trials for treatment 
of asthma and allergic diseases
Name Source Target Development
Status
Omalizumab Humanized IgE FDA-approved
Lumiliximab Chimeric FcERII (CD23) Phase II
Soluble IL-4
receptor
Fusion protein IL-4 Phase II
AMG-317 Human IL-4Ra receptor Phase II
Aerovant Mutein IL-4Ra receptor Phase II
Mepolizumab Humanized IL-5 Phase II





CAT-354 Human IL-13 Phase II
Lebrikizumab Humanized IL-13 Phase II
IMA-638 Humanized IL-13 Phase II
QAX 576 mAb IL-13 Phase II
TH-2 CYTOKINE INHIBITORS
Because of the importance of Th-2 cytokines, IL-4, IL-5, IL-9,  
and IL-13, strategies aimed at inhibiting their production or ef-
fects have been tried in human clinical trials (Table). Initial at-
tempts to use strategies aimed at IL-4 showed some promise, 
but subsequent large scale studies were unrewarding. This has 
included soluble IL-4 receptors and monoclonal antibodies 
against IL-4. 
There are several strategies aimed at IL-4Ra, the common re-
ceptor chain important for both IL-4 and IL-13 signaling. AMG 
317, is a humanized monoclonal antibody to IL-4Ra that has 
undergone initial human clinical trials.
9 Early trials have been 
disappointing with some minor biologic activity but no clinical 
effects. Nonetheless, further development of this molecule is 
warranted since different routes and dosages may be important 
in showing clinical effectiveness. An inhaled anti-sense mole-
cule to IL-4Ra, AIR645 has also undergone very early clinical tri-
als, but no positive clinical effects have been reported thus far. 
A 14 kD IL-4 mutein that blocks IL-4Ra has been shown to be 
effective for both atopic dermatitis when given subcutaneously 
and asthma when given by inhalation. The inhaled form of this 
molecule, pitrakinra (AEROVANT
TM) was reported to block ear-
ly and late phase allergen responses in patients with asthma.
10 
Its efficacy in large scale clinical trials with traditional primary 
endpoints has yet to be determined. 
Murine model studies have shown that IL-13 plays an impor-
tant role in airway hyperresponsiveness, mucus production, se-
cretion of eotaxin, and airway remodeling. There are several hu-
manized monoclonal antibodies against IL-13 that are currently 
under development in phase I or phase II human clinical trials. 
CAT-354 is a human monoclonal anti-IL-13 antibody that is in 
a phase IIa parallel-arm study to evaluate the efficacy and safe-
ty of three subcutaneous treatment regimens in adult subjects 
with uncontrolled, moderate-to-severe, persistent asthma (Clin-
icalTrials.gov Identifier: NCT00873860).
Lebrikizumab is a humanized monoclonal antibody that binds 
to IL-13 and is currently in development for asthma (ClinicalTri-
als.gov Identifier: NCT00930163). A phase II clinical trial evalu-
ating the effects of this antibody in patients with asthma is on-
going However, mono-specific anti-IL-13 strategies have been 
disappointing in recently reported trials despite IL-13’s putative 
importance in asthma pathogenesis. It is unclear if there is a 
problem with the specific monoclonal antibodies that have 
been developed or if there is too much redundancy in the im-
mune system such that inhibiting either IL-4 or IL-13 is insuffi-
cient. Indeed, strategies aimed at both IL-4 and IL-13 may be a 
better option.
A monoclonal antibody aimed at interleukin-9 is in early phase 
clinical trials. However, no published data are available to ascer-
tain its potential efficacy and safety. 
Suplatast tosilate is an oral agent that has been shown to in-
hibit the synthesis of both IL-4 and IL-5.
11 Suplatast has been 
shown in early clinical trials to decrease serum IgE and periph-
eral blood eosinophil counts.
12 Suplatast has also been shown 
to improve traditional asthma outcomes and decrease airway 
inflammation.
13 However, this molecule has to be used in a 
three times per day regimen making its utility somewhat prob-
lematic since compliance would clearly be an issue.
ANTI-EOSINOPHIL STRATEGIES
Considering the prominence of eosinophils in many patients 
with asthma and their putative role in the pathogenesis of aller-
gic respiratory disorders, several therapeutic approaches have 
been developed to block eosinophil-mediated effects. Initial 
strategies have involved using humanized monoclonal anti-
bodies against interleukin-5, an important cytokine for both 
chemotaxis and differentiation of eosinophils. Several older 
studies have confirmed reductions in blood and sputum eo-
sinophils without significant changes in airway hyperrespon-
siveness, lung functions or symptoms in patients treated with 
anti-Il-5 monoclonal antibodies. Two recent studies investigat-
ed different aspects of mepolizumab therapy in patients with 
refractory asthma and sputum eosinophilia.
14,15 Unlike previous 
studies, in order to enroll in these two studies, subjects had to 
have a high sputum eosinophil count, greater than 3%. The in-
vestigators once again found a reduction in peripheral blood 
eosinophil counts. However, clinical effects were modest with 
either no or little effects on FEV1, airway hyperresponsiveness 
or symptoms. There were however significant reductions in 
asthma exacerbations. Nonetheless, it is unclear how useful 
this strategy will be given that in these two studies, less than 5% 
of uncontrolled asthma patients met the entry criteria of having Dimov et al. Volume 2, Number 4, October 2010
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greater than 3% sputum eosinophils. Thus, the treatment ap-
pears effective for a small segment of uncontrolled asthma pa-
tients, and even in those subjects, therapeutic effectiveness was 
somewhat modest.
TPIASM8 is an oligonucleotide using RNA silencing. It con-
tains two modified phosphorothioate anti-sense oligonucle-
otides designed to inhibit allergic inflammation by down-regu-
lating human CCR3 and the common beta-chain of IL-3, IL-5 
and GM CSF. A recent study examined the effects of inhaled 
TPIASM8 on sputum cellular influx, CCR3 and beta-chain 
mRNA in protein levels and airway physiologic responses after 
inhaled allergen challenge.
16 Compared with placebo, TPI-
ASM8 inhibited sputum eosinophil influx by 46% and blunted 
the increase in total cells after allergen challenge. TPIASM8 sig-
nificantly reduced the early asthmatic response, but not the late 
asthmatic response. The allergen-induced levels of beta-chain 
mRNA and CCR3 mRNA in sputum-derived cells were inhibit-
ed by TPIASM8, but no significant effects on cell surface pro-
tein expression of CCR3 and the beta-chain were found. Larger 
scale clinical trials are necessary to discern the effectiveness of 
this treatment for asthma.
A humanized monoclonal antibody against GM CSF is also 
undergoing very early clinical trials. However, no data have 
been published to date.
ANTI-TNF-a STRATEGIES
TNF-a has a number of effects that could be important in asth-
ma. TNF-a can increase airway hyperresponsiveness and in-
crease the expression of key adhesion molecules important for 
eosinophil and neutrophil chemotaxis. Moreover, TNF-a can 
stimulate both epithelial and endothelial cells to synthesize and 
release chemokines and other cytokines. Several small studies 
in patients with severe asthma have shown that patients treated 
with TNF-a blockers have some improvements in lung func-
tion, quality of life, exacerbation rates and airway hyperrespon-
siveness. However, larger multi-site studies have been disap-
pointing. Not only has efficacy been difficult to show, but in-
creased adverse events were recorded indicating a relatively 
poor risk to benefit ratio.
17 Thus, anti-TNF strategies have been 
placed on hold for further development in the management of 
asthma and allergic disorders.
STRATEGIES AIMED AT IGE AND MAST CELLS
An attractive target for effectively managing allergic inflam-
mation is the mast cell. One target in the mast cell that is critical 
for degranulation is Syk kinase. Syk kinase is an intracellular pro-
tein tyrosine kinase that is important in mast cell and basophil 
activation and mediator release. Upon cross-linking of IgE 
bound high affinity IgE receptors, Syk kinase is activated and 
leads to degranulation, cytokine synthesis and leukotriene syn-
thesis. Two antagonists, R112 and R343, have been tried in hu-
man studies. R112 demonstrated statistically significant effica-
cy in ameliorating symptoms of allergic rhinitis including nasal 
congestion, nasal discharge, sneezing, nasal and throat pruri-
tus, post nasal drip, cough, headache and facial pain in a two-
day seasonal allergic rhinitis park study setting.
18 The onset of 
action was observed within 30 to 90 minutes and the overall 
clinical improvement over placebo was approximately 25%. An 
inhaled formulation, R343, is currently being developed for the 
management of allergic asthma.
19 
Omalizumab, the humanized monoclonal anti-IgE antibody, 
has been shown to have a number of anti-inflammatory and 
clinical benefits in patients.
19,20 In patients on inhaled corticos-
teroids alone or in combination with other agents, the addition 
of omalizumab has been shown to reduce asthma exacerba-
tions, improve symptom scores, reduce the need for inhaled 
and oral corticosteroids and decrease the necessity of rescue 
medication.
21-24 Efficacy has also been demonstrated in patients 
who have concomitant allergic rhinitis and asthma.
20 
Omalizumab has been shown in several small studies or case 
reports to have some benefits in the following disorders: sea-
sonal and perennial allergic rhinitis with and without asthma; 
atopic dermatitis; food allergies; insect allergy; chronic urticar-
ia with auto-antibodies to either the high affinity IgE receptor 
or IgE itself; allergic broncho-pulmonary aspergillosis; latex al-
lergy; chronic hyperplastic sinusitis; recurrent nasal polyposis; 
drug allergy; and idiopathic anaphylaxis.
21 
Omalizumab decreases free IgE levels rapidly and the expres-
sion of the high affinity IgE receptor expression on key effector 
cells, including mast cells, basophils, dendritic cells and mono-
cytes. In addition, lung inflammation has been shown to de-
crease after only sixteen weeks of omalizumab treatment. How-
ever, omalizumab has been reported to cause anaphylaxis 
through unknown mechanisms in first as well as subsequent 
doses.
22 
Observation of patients for 2 hours after they received each of 
the first three injections and for 30 minutes after they received 
subsequent injections would capture 75% of the anaphylactic 
reactions according to the current recommendation of the 
American Academy of Allergy, Asthma & Immunology/Ameri-
can College of Allergy, Asthma & Immunology Joint Task 
Force.
23
MAST CELL MEDIATOR ANTAGONISTS
There have been many attempts to develop antagonists to 
mast cell mediators that play a significant role in airway hyper-
reactivity in asthma. Antagonists to CRTH2 (a G protein cou-
pled receptor) are currently under investigation. CRTH2 is pres-
ent on Th2-cells, eosinophils and basophils mediating activa-
tion and chemotaxis to PGD2. A recent 28-day phase II study in 
mild to moderate asthma patients with FEV1 values between Immunomodulators for Asthma AAIR 
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60 and 80% showed promising trends with ACT-129968, an oral 
antagonist.
24 Bronchoprovocation to both adenosine mono-
phosphate and methacholine decreased by one to one and a 
half doubling doses, FEV1 increased by 10 to 14%, and there 
was a decrease in sputum eosinophils and IgE. Moreover, pa-
tients had an improved quality of life. Further studies examin-
ing the efficacy of this approach will be necessary to determine 
true therapeutic potential. 
SUMMARY
There are a number of immunomodulators that have been 
developed for the treatment of allergic disorders. Some have 
looked very promising in pre-clinical trials, but have not shown 
significant benefits in human clinical trials indicating the dis-
parity between murine models and human asthma. 
It is difficult to predict which of these pharmaceutical agents 
other than omalizumab will achieve success. Ultimately, the 
use of these putative therapeutics in human clinical trials should 
help define the pathogenesis of asthma and determine the im-
portance of specific molecules in large patient populations. It is 
possible that some of these agents could be effective for only a 
small sub-population of patients which potentially would make 
them unlikely to be commercially viable. 
The search for better therapeutics options is focused on de-
creasing the symptoms and improving the quality of life while 
preventing or altering disease course. These molecules should 
also have a favorable risk benefit ratio which would lead to wid-
er use. In addition, cost effective strategies are clearly indicated 
as monoclonal antibodies are very expensive to manufacture 
and to administer. 
The use of immunomodulators for the treatment of allergic 
respiratory disorders represents an exciting new era for the ther-
apy of allergic disorders. Human clinical trials are essential for 
the development and to determine their ultimate place in our 
therapeutic armamentarium.
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